Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review

Simple item page
dc.contributor.authorAbla, Dima
dc.contributor.authorAbboud, Miguel Raul
dc.contributor.authorNoun, Dolly
dc.contributor.authorTarek, Nidale
dc.contributor.authorPemmaraju, Naveen
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:11:12Z
dc.date.available2025-01-24T12:11:12Z
dc.date.issued2022
dc.description.abstractBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare type of leukemia in children, Although BPDCN is a chemo-sensitive tumor, the relapse rate is very high. Tagraxofusp, which is a CD123-directed cytotoxin has been used as a targeted therapy and has shown promising results in patients with either untreated or relapsed BPDCN. There is also a good response with Venetoclax, a selective BCL2 inhibitor, as a single agent or in combination with chemotherapy. Here, we described a case of a pediatric patient with BPDCN who was treated initially with ALL-based regimen followed by Allogeneic hematopoietic stem-cell transplantation (HSCT) and salvaged with Hyper-CVAD combined with Venetoclax after testicular relapse 11 months post Allogeneic HSCT. © 2022 The Authors
dc.identifier.doihttps://doi.org/10.1016/j.lrr.2022.100313
dc.identifier.urihttp://hdl.handle.net/10938/32518
dc.language.isoen
dc.publisherElsevier Ltd
dc.sourceScopus
dc.subjectDendritic
dc.subjectLeukemia
dc.subjectNeoplasm
dc.subjectPlasmacytoid
dc.subjectVenetoclax
dc.subjectAsparaginase
dc.subjectBusulfan
dc.subjectCd123 antigen
dc.subjectCd16 antigen
dc.subjectCd4 antigen
dc.subjectCd56 antigen
dc.subjectCommon acute lymphoblastic leukemia antigen
dc.subjectCyclophosphamide
dc.subjectCyclosporine
dc.subjectCytarabine
dc.subjectDaunorubicin
dc.subjectDexamethasone
dc.subjectDoxorubicin
dc.subjectFludarabine
dc.subjectHla dr antigen
dc.subjectHydrocortisone
dc.subjectMethotrexate
dc.subjectPrednisone
dc.subjectReceptor type tyrosine protein phosphatase c
dc.subjectTagraxofusp
dc.subjectThiotepa
dc.subjectThymocyte antibody
dc.subjectVincristine
dc.subjectAbdominal pain
dc.subjectAllogeneic hematopoietic stem cell transplantation
dc.subjectAnemia
dc.subjectArticle
dc.subjectBacteremia
dc.subjectBlastic plasmacytoid dendritic cell neoplasm
dc.subjectBone marrow biopsy
dc.subjectCancer chemotherapy
dc.subjectCancer recurrence
dc.subjectCase report
dc.subjectChild
dc.subjectClinical article
dc.subjectCoronavirus disease 2019
dc.subjectDendritic cell sarcoma
dc.subjectDrug dose reduction
dc.subjectEchography
dc.subjectFlow cytometry
dc.subjectHuman
dc.subjectHuman tissue
dc.subjectImmunohistochemistry
dc.subjectMale
dc.subjectMultiple cycle treatment
dc.subjectMultiplex polymerase chain reaction
dc.subjectNeutropenia
dc.subjectPlatelet count
dc.subjectPositron emission tomography
dc.subjectReciprocal chromosome translocation
dc.subjectRelapse
dc.subjectSchool child
dc.subjectThrombocytopenia
dc.subjectWhole body radiation
dc.titleHyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2022-5704.pdf
Size:
2.06 MB
Format:
Adobe Portable Document Format
Download

Collections

Pediatrics and Adolescent Medicine